Cancer
Synthetic glabridin derivative restores salivary function by regulating metabolism and immunity in Sjögren’s
In a new study published in Experimental & Molecular Medicine, researchers report promising therapeutic effects from a synthetic glabridin derivative...
Study Explains Why DNA Damage from Smoking or UV Causes Cancer in Some
Scientists have uncovered direct evidence that inherited genetics can steer how cancers emerge and evolve, even after the same environmental...
Genetic Makeup Predicts Cancer Patients’ Benefits and Side Effects from Immunotherapy
Viral CAR-T cell therapy has transformed treatment options for aggressive blood cancers, yet its benefits and risks vary widely among...
HDAC6 Serves as Biomarker for B-ALL Dissemination and Relapse
HDAC6, a cytoplasmic deacetylase best known for shaping cell stress responses, is emerging as an unusually informative flag in blood...
Nonreproductive Tumor Progression Disrupts Ovarian Function via CXCL10–IL18R1 Signaling
A new study from researchers in 2026 reports that tumor progression can disrupt ovarian function even when tumors are not...
Discovering what shapes white blood cells may enable new cancer therapies
In leukemia’s most aggressive settings, bone marrow–resident blood-cell factories fail to complete normal maturation. Instead of rapidly generating mature immune...
Advances Toward Liquid Biopsy Profiling of Antitumor Immune Responses
Tumour biopsy remains the clinical gold standard for diagnosing cancer and guiding biomarker-based treatment choices. By interrogating the tumour itself,...
Engineered Gut Bacteria Target Pancreatic Cancer in Promising Drug-Like Study
Pancreatic cancer is notoriously resistant to immunotherapy because many tumors develop an immune-suppressive, oxygen-poor “cold” microenvironment that blocks effective T...
Survival Outcomes Linked to Timing of Immune Checkpoint Inhibitor Dosing
A new analysis from a large, single-centre cohort suggests that when immune checkpoint inhibitors are given can meaningfully shape outcomes...
Randomized Phase II Trial Tests Nivolumab Then Nivolumab-Ipilimumab or Docetaxel
A new randomized Phase II clinical trial, OPTIM, is testing whether escalating immune therapy can improve outcomes for people with...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!